 | • レポートコード：D-MOR01011 • 出版社/出版日：Mordor Intelligence / 2019年12月26日 • レポート形態：英文、PDF、129ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：遺伝子 |
| Single User | ￥629,000 (USD4,250) | ▷ お問い合わせ |
| Multi User | ￥703,000 (USD4,750) | ▷ お問い合わせ |
| Global Site License | ￥1,110,000 (USD7,500) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートはエピジェネティクスについて総合的に分析し、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、キット別（亜硫酸水素塩変換キット、チップシーケンスキット、RNAシーケンスキット、全ゲノム増幅キット、5-HMCおよび5-MC分析キット、その他）分析、試薬別（抗体、バッファー、ヒストン、磁気ビーズ、プライマー、その他）分析、酵素別（DNA修飾酵素、タンパク質修飾酵素、RNA修飾酵素）分析、器具別（質量分析計、ソニケーター、次世代シーケンサー、その他）分析、器具別（質量分析計、ソニケーター、次世代シーケンサー、その他）分析、用途別（腫瘍学、非腫瘍学、発生生物学、その他）分析、技術別（DNAメチル化、ヒストンのメチル化、ヒストンアセチル化、ラージノンコーディングRNA、 MicroRNAモディフィケーション、クロマチン構造）分析、地域別（北米、ヨーロッパ、アジア太平洋、中東およびアフリカ、南米）分析、競争状況、市場機会および将来動向に区分して収録しています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・エピジェネティクスの世界市場：キット別（亜硫酸水素塩変換キット、チップシーケンスキット、RNAシーケンスキット、全ゲノム増幅キット、5-HMCおよび5-MC分析キット、その他） ・エピジェネティクスの世界市場：試薬別（抗体、バッファー、ヒストン、磁気ビーズ、プライマー、その他） ・エピジェネティクスの世界市場：酵素別（DNA修飾酵素、タンパク質修飾酵素、RNA修飾酵素） ・エピジェネティクスの世界市場：器具別（質量分析計、ソニケーター、次世代シーケンサー、その他） ・エピジェネティクスの世界市場：用途別（腫瘍学、非腫瘍学、発生生物学、その他） ・エピジェネティクスの世界市場：技術別（DNAメチル化、ヒストンのメチル化、ヒストンアセチル化、ラージノンコーディングRNA、 MicroRNAモディフィケーション、クロマチン構造） ・エピジェネティクスの世界市場：地域別（北米、ヨーロッパ、アジア太平洋、中東およびアフリカ、南米） ・競争状況 ・市場機会および将来動向 |
Epigenetics Market – Growth, Trends, and Forecast (2019 – 2024)
Market Overview
Cancer rates could further increase by 50%, to 15 million new cases, by 2020, as per the World Cancer Report. It also provides clear evidence that healthy lifestyles and public health action by governments and health practitioners can prevent as many as one-third of cancers, worldwide. The American Cancer Society, estimated in 2016, that there were 1,685,210 new cancer cases and about 595,690 deaths due to cancer, in the United States. The National Cancer Institute reported that more than 60% of the world’s new cancer cases occur in Africa, Asia, and Central and South America. About 70% of the worldwide deaths due to cancer occur in these regions.
According to the WHO, almost 70% of deaths from cancer occur in low and middle-income countries, and only one in five low- and middle-income countries has the necessary data to drive cancer-related policies. This worldwide and extensive threat of cancer remains a major driver for the development of new cancer therapies that help in risk assessment, early diagnosis, and effective monitoring of the treatment.
Cancer resistance to treatment is a major obstacle. However, epigenetic drugs, on their own or in combination with other drugs, can be a viable alternative. The epigenetic drug used in the laboratory study stops the ability of cancer cells to hide from the immune system and makes the tumor vulnerable. So, increasing prevalence of cancer will augment the growth of the epigenetics market.
Scope of the Report
As per the scope of this report, epigenetics, in simple terms, refers to the study of genetic effects that are not entirely encoded by the DNA sequence of an organism. Epigenetics mainly deals with gene expression. Epigenetics also refers to changes in the genome in terms of functionality, which do not involve a change in the nucleotide sequence. The DNA methylation or histone modification is a type of mechanism that causes epigenetic changes.
Key Market Trends
By Technology Segment, DNA methylation is Expected to Hold Largest Share Over the forecast period
DNA methylation dominated the global epigenetics market as it is covalent addition of a methyl group in cytosine ring, which leads to inhibition of transcription. Sensitive bisulfite modification followed by PCR is called methylation sensitive PCR (MSP). Real-time PCR for methylation detection, methyl light, and quantitative analysis of methylated alleles are variations of MSP. Currently, quantitative methods such as allele-specific bisulphite sequencing, southern-based method, bisulphite pyrosequencing, and bisulphite PCR followed by MALDI – TOF MS are also useful for DNA methylation. Advancements in technologies are increasingly enabling assessment of locus-specific DNA methylation on a genome wide scale.
North America Region Holds the Largest Market Share of Epigenetics Market
North America dominates the epigenetics market, owing to rapid developments in healthcare infrastructure, the presence of major players in the region, huge investments made in the research and development. With increasing investments being made in the R&D of products by industries, an increase in the demand for protein expression systems is expected, as many mammalian proteins, such as growth hormone, insulin, antibodies, and vaccines are produced industrially. In recent years, biopharmaceutical sales have reached 30% of all new pharmaceutical sales in the country. The United States accounts for the world’s largest expenditure on healthcare research. All these factors will augment the growth of the studied market.
Competitive Landscape
The market competition is set to intensify as several key players are focusing on the expansion of their epigenetics portfolio through acquisition and collaboration with companies. The epigenetics market is expected to open up several opportunities for new players as well as currently established market leaders.
Reasons to Purchase this report:
The market estimate (ME) sheet in Excel format
Report customization as per the client’s requirements
3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Incidence and Prevalence of Cancer
4.2.2 Increasing Funding for R&D in Healthcare
4.2.3 Rising Epigenetic Applications in Non-oncology Diseases
4.3 Market Restraints
4.3.1 Rising Costs of Instruments
4.3.2 Dearth of Skilled Researchers
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Kit
5.1.1 Bisulfite Conversion Kit
5.1.2 Chip-seq Kit
5.1.3 RNA Sequencing Kit
5.1.4 Whole Genome Amplification Kit
5.1.5 5-HMC and 5-MC Analysis Kit
5.1.6 Other Kits
5.2 By Reagent
5.2.1 Antibody
5.2.2 Buffer
5.2.3 Histone
5.2.4 Magnetic Bead
5.2.5 Primer
5.2.6 Other Reagents
5.3 By Enzyme
5.3.1 DNA Modifying Enzyme
5.3.2 Protein Modifying Enzyme
5.3.3 RNA Modifying Enzyme
5.4 By Instrument
5.4.1 Mass Spectrometer
5.4.2 Sonicator
5.4.3 Next-generation Sequencer
5.4.4 Other Instruments
5.5 By Application
5.5.1 Oncology
5.5.2 Non-oncology
5.5.2.1 Inflammatory Diseases
5.5.2.2 Metabolic Diseases
5.5.2.3 Infectious Diseases
5.5.2.4 Cardiovascular Diseases
5.5.2.5 Other Non-oncology Applications
5.5.3 Developmental Biology
5.5.4 Other Research Areas
5.6 By Technology
5.6.1 DNA Methylation
5.6.2 Histone Methylation
5.6.3 Histone Acetylation
5.6.4 Large Noncoding RNA
5.6.5 MicroRNA Modification
5.6.6 Chromatin Structures
5.7 Geography
5.7.1 North America
5.7.1.1 US
5.7.1.2 Canada
5.7.1.3 Mexico
5.7.2 Europe
5.7.2.1 Germany
5.7.2.2 UK
5.7.2.3 France
5.7.2.4 Italy
5.7.2.5 Spain
5.7.2.6 Rest of Europe
5.7.3 Asia Pacific
5.7.3.1 China
5.7.3.2 Japan
5.7.3.3 India
5.7.3.4 Australia
5.7.3.5 South Korea
5.7.3.6 Rest of Asia-Pacific
5.7.4 Middle East and Africa
5.7.4.1 GCC
5.7.4.2 South Africa
5.7.4.3 Rest of Middle East and Africa
5.7.5 South America
5.7.5.1 Brazil
5.7.5.2 Argentina
5.7.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Abcam PLC
6.1.2 Active Motiff
6.1.3 Diagenode Inc
6.1.4 Illumina Inc
6.1.5 Merck & Co., Inc
6.1.6 Qiagen NV
6.1.7 Sigma Aldrich Corporation
6.1.8 Thermo Fisher Scientific
6.1.9 Zymo Research Corporation
6.1.10 F. Hoffmann-La Roche Ltd
7 MARKET OPPORTUNITIES AND FUTURE TRENDS